| Antimicrobial agent |
Percentage (%) of isolates |
| Non-ESBL |
ESBL |
MBL |
ESBL+MBL |
| S |
I |
R |
S |
I |
R |
S |
I |
R |
S |
I |
R |
| CSE1034 |
100 |
0 |
0 |
74.1 |
22.7 |
3.1 |
97.3 |
0 |
0 |
95.1 |
1.6 |
3.3 |
| Piperacillin+tazobactam |
100 |
0 |
0 |
84.3 |
12.2 |
3.5 |
0 |
0 |
100 |
0 |
14.7 |
85.3 |
| Cefepime |
100 |
0 |
0 |
28.5 |
6.3 |
65.1 |
0 |
0 |
100 |
0 |
8.2 |
91.8 |
| Ceftazidime |
100 |
0 |
0 |
44.8 |
10.8 |
44.3 |
0 |
0 |
100 |
0 |
11.5 |
88.5 |
| Imipenem |
100 |
0 |
0 |
66.5 |
17.7 |
15.8 |
0 |
0 |
100 |
0 |
9.8 |
90.2 |
| Meropenem |
100 |
0 |
0 |
54.7 |
31.7 |
13.6 |
0 |
0 |
100 |
0 |
11.5 |
88.5 |
| Doripenem |
100 |
0 |
0 |
83.8 |
12.8 |
3.4 |
11.3 |
86.6 |
2.1 |
19.5 |
77.7 |
2.8 |
Here, S=susceptible; I: intermediate; R=resistant. |
